Page last updated: 2024-12-09
tifacogin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Tifacogin: a recombinant form of tissue factor pathway inhibitor, RN & amino acid sequence in first source; MW about 32 kDa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 961320 |
| SCHEMBL ID | 3625005 |
| MeSH ID | M0352035 |
Synonyms (22)
| Synonym |
|---|
| 148883-56-1 |
| AKOS000226216 |
| 1-phenyl-n-(thiophen-2-ylmethyl)methanamine |
| STK510839 |
| SCHEMBL3625005 |
| tifacogin |
| benzyl(thiophen-2-ylmethyl)amine |
| FT-0643425 |
| n-benzyl-1-(thiophen-2-yl)methanamine |
| 73325-61-8 |
| 2-thienyl n-benzyl methyl amine |
| mfcd01764729 |
| benzyl-thiophen-2-ylmethyl-amine |
| benzylthiophen-2-ylmethylamine |
| blood-coagulationfactor laci(human clone lp9 protein moiety reduced),n-l-alanyl- |
| 1-phenyl-n-[(thiophen-2-yl)methyl]methanamine |
| DTXSID70933497 |
| (2r)-(-)-glycidyl4-nitrobenzoate |
| 1-phenyl-n-(2-thienylmethyl)methanamine |
| YFA88356 |
| CS-0213282 |
| benzyl[(thiophen-2-yl)methyl]amine |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR. " | ( Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Abraham, E; Artigas, A; Beale, R; Creasey, AA; De Deyne, C; Demeyer, I; Doig, C; Laterre, PF; Light, B; Opal, S; Peckelsen, C; Percell, SR; Pettilä, V; Poole, L; Postier, R; Reinhart, K; Rodriguez, AL; Seibert, A; Shu, V; Simon, S; Spapen, H; Sprung, CL; Stolzenbach, JC; Stone, J; Svoboda, P; Tobias, J; Zwingelstein, C, 2003) | 0.98 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6." | ( Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Abraham, E; Artigas, A; Beale, R; Creasey, AA; De Deyne, C; Demeyer, I; Doig, C; Laterre, PF; Light, B; Opal, S; Peckelsen, C; Percell, SR; Pettilä, V; Poole, L; Postier, R; Reinhart, K; Rodriguez, AL; Seibert, A; Shu, V; Simon, S; Spapen, H; Sprung, CL; Stolzenbach, JC; Stone, J; Svoboda, P; Tobias, J; Zwingelstein, C, 2003) | 0.86 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.03) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (23.08%) | 5.53% |
| Reviews | 3 (23.08%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (53.85%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||